-Andres J P Klein-Szanto Researcher Activity Profile

Research Author Detailed Information 

Andres J P Klein-Szanto Publication Rate By Year

Andres J P Klein-Szanto has published 1 paper(s) in 1993, 1 paper(s) in 2004, 2 paper(s) in 2006, 11 paper(s) in 2007, 2 paper(s) in 2008, for a total of 17 research publications in total.

Andres J P Aj Klein-Szanto Author Information

LAST NAME: klein-szanto

FIRST NAME: Andres J P

INITIALS: aj

AFFILIATION:

Papers

Andres J P Klein-Szanto's Publication Record

1. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Year Published: 2006
Laboratory of Molecular Oncology and Cell Cycle Regulation, Department of Medicine (Hematology/Oncology), University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
2. Activation of the mTOR signaling pathway in renal clear cell carcinoma. Year Published: 2006
Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
3. Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. Year Published: 2007
Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
4. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. Year Published: 2007
University of Arizona Cancer Center, Tucson, AZ, USA.
5. Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers. Year Published: 2007
Biotherapeutics Development Lab, Harvard Institute of Human Genetics, Harvard Medical School and Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
6. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Year Published: 2007
Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
7. Inhibition of proprotein convertases: approaches to block squamous carcinoma development and progression. Year Published: 2007
Department of Pathology and Tumor Cell Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
8. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Year Published: 2007
Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
9. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Year Published: 2007
The Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
10. IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Year Published: 2007
Gastroengerology Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
11. IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Year Published: 2007
Gastroengerology Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
12. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Year Published: 2007
The Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
13. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Year Published: 2007
Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
14. Cellular and molecular changes during mouse skin tumor progression. Year Published: 1993
Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA 19111.
15. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. Year Published: 2008
Laboratory of Molecular Oncology and Cell Cycle Regulation, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
16. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Year Published: 2008
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA. qhuang@wistar.org
17. Frequent activation of AKT2 kinase in human pancreatic carcinomas. Year Published: 2004
Human Genetic Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.